二甲双胍对中老年代谢综合征脂联素的影响

Effect of Metformin on Plasma Adiponectin Levels in Middle and Old Aged Patients with Metabolic Syndrome

目的:观察二甲双胍对代谢综合征(MS)的干预效果及可能机制。方法:将124例MS患者随机分为两组,生活方式干预组仅行生活方式干预,二甲双胍组在此基上加服二甲双胍,干预前及干预后半年分别测量体重指数(BMI)、收缩压和舒张压(SBP、DBP)、空腹血糖(FBG)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、血浆脂联素水平(APN)、空腹胰岛素(FINS),并计算胰岛素敏感性指数(ISI)等。结果:治疗后两组SBP、DBP、TG均较干预前明显下降(P<0.01),两组间无明显差异(P>0.05);二甲双胍组BMI、FBG、FINS较前明显下降,APN、ISI较前明显升高(P<0.01),而生活方式干预组上述指标的变化不明显(P>0.05),两组比较有显著性差异(P<0.01、P<0.05)。结论:非糖尿病MS患者口服二甲双胍半年后APN水平和ISI明显升高,MS 5项指标均明显改善。

Objective： To investigate the effect and mechanism of metformin on patients with metabolic syndrome （MS）. Methods： A total of 124 patients were divided randomly into life-style modified group （n=62） and metformin treatment plus lifestyle intervention group （n=62）. Body mass in- dex （BMI）, blood pressure, fasting blood glucose （FBG）, triglyceride （TG）, high density lipo- protein-cholesterol （HDL-C）, plasma adiponectin （APN）, and fasting insulin （FINS） of each group were detected and compared after half one year. Insulin sensitivity index （ISI） was calcu- lated based on FBG and FINS. Results： Blood pressure and TG levels were lower than those be- fore treatment in both groups （both P〈0.01）, and there was no statistic difference between the two groups. Levels of BMI, FBG, and FINS were lower and levels of APN and ISI were higher in metformin group than in life-style modified group （P〈0.01 or P〈0.05）. Conclusion： There was a significant increase in APN level and ISI, and the five indicators of MS were improved in non-di- abetic middle and old aged MS patients after half one year treatment with metformin.